West Nile virus detected in NYC mosquitoes as experts track rise in U.S. cases
While no human cases have not been reported in New York City so far in 2025, the virus has been found in mosquitoes.
The NYC Department of Health reported mosquitoes tested positive for West Nile virus in Staten Island, Queens and the Bronx.
According to the Centers for Disease Control and Prevention, at least 49 human cases have been reported in 15 states, including Arizona, Louisiana and Texas, so far this year.
"There are more cases than have been identified," Dr. Nischay Mishra, an associate professor at Columbia University Medical Center, said.
He said cases are being reported this year in counties not seen in the past.
"Kind of concerned, especially because we have not reached the peak season of the West Nile virus yet," he said.
Mishra said peak season for West Nile virus is in August and September.
According to the Environmental Protection Agency, climate change increases the risk of human exposure to West Nile virus.
Monday's torrential rain and flash flooding followed by several days of high humidity in the Tri-State Area made it difficult for pools of water to evaporate, and created breeding grounds for mosquitoes.
City residents are required to eliminate standing water to help prevent mosquitoes from breeding.
Experts say it's also vital to protect yourself from bites.
"The key here is to use mosquito repellents with DEET or picaridin," said Dr. Celine Grounder.
NYC Health said it monitors mosquito populations and applies pesticides during the summer to reduce the spread of viruses.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
PDO Max Launches LúmEnvy Skincare Brand: Medical-Grade Skincare for At-Home Glow
Consumers can now experience the glow of professional facials at home— with no downtimeand real results SYRACUSE, N.Y., July 24, 2025 /PRNewswire/ -- PDO Max, the medical aesthetics brand known for its industry-leading professional PDO threads and skin boosters, announces the launch of its groundbreaking at-home skincare brand, LúmEnvy Skincare. The new line, featuring clinical strength skincare routines, topicals, and tools, empowers consumers to extend and maintain professional medspa results, delivering a radiant, healthy glow directly from the comfort of their homes. LúmEnvy Skincare was created around two powerful ingredients: PDRN (derived from salmon DNA) and Centella Asiatica, a plant exosome known for its healing properties. PDRN, a cutting-edge ingredient widely used in medical aesthetics, promotes skin regeneration, improves elasticity, brightens complexion, and reduces inflammation. Centella Asiatica helps soothe skin, promotes collagen, and enhances moisture retention. Together, these ingredients work to refresh your skin, smooth its texture, and boost its natural glow. It's a game-changer for at-home skincare, making advanced skin health easy and convenient for everyone. The new LúmEnvy Skincare introduces its first-of-its-kind Glow Between™ Box, a 12-week at-home regimen that includes: LúmEnvy Serum featuring PDRN, Centella Asiatica, hyaluronic acid, vitamin C, and niacinamide Glowpin Applicator, inspired by microneedling and infused with PDRN, vitamin B12, and amino acids Five pro-collagen sheet masks for deep hydration and a radiant, glass-skin finish. The full LúmEnvy Skincare collection also includes professional-grade tools like the Valluxia Infrared Mask, Dermaplasion Facial Tool, and Facial Sculptor—designed to bring medspa-level skincare to everyday routines. "We created LúmEnvy Clinical (found only at medspas) last year as a more concentrated PDRN formula with five impactful ingredients to be paired with lasers and microneedling treatments," said Giovanna McCarthy, Founder of PDO Max. "That amazing glow you get after a medspa visit should continue through to your next professional touch, and with LúmEnvy Skincare we're giving our customers access to those high-quality ingredients and tools typically found in professional settings, so they can keep their skin glowing every day." Rooted in science and powered by purpose, LúmEnvy is more than skincare—it's a ritual of self-expression and self-care. Created by women who understand the transformative power of investing in yourself, LúmEnvy celebrates the Glow Between: the quiet confidence that exists between who you are and how you show up in the world. Every product is crafted to deliver real results while making every moment with your skin feel intentional, empowering, and personal. To learn more and purchase, visit About PDO MaxFounded in 2017 by Giovanna McCarthy, PDO Max is a women-led medical aesthetics company that designs and manufactures FDA-cleared PDO thread-in-cannula devices for soft tissue approximation, as well as clinical-grade topical skin boosters. PDO Max supports aesthetic practices across nationwide through training, device innovation, and science-based skincare solutions. For media requests, including interviews, please contact:Erika SiemaskoFACTEUR PR for PDO Max978-270-2777398482@ View original content: SOURCE PDO Max
Yahoo
17 minutes ago
- Yahoo
Plexision Secures Funding to Bring Artificial Intelligence to Transplant Outcome Care
New investment to advance personalized transplant medicine using AI-enhanced cell-based testing PITTSBURGH, July 24, 2025--(BUSINESS WIRE)--Plexision, a biotechnology company, today announced a $365,000 investment from the Richard King Mellon Foundation. The funds will be used to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities across Plexision's suite of cell-based blood tests, significantly improving predictive accuracy for complex transplant outcomes. Despite advances in transplant medicine, managing immunosuppressive drugs remains a delicate balance. Too little medication can lead to rejection, which can be cell- or antibody-mediated, while too much can increase the risk of infections with different viruses, and in some cases, lymphoma related to Epstein-Barr virus (EBV). Legacy testing tools on the market offer limited visibility into a patient's immune status, and provide reactive, binary results. To distinguish between the various types of rejection and infection, clinicians often integrate other clinical data to make treatment decisions. Plexision's blood tests predict the most common rejection subtypes and post-transplant infections, all using a common platform of immune cell function. When integrated with machine learning, this test panel ranks risks of multiple outcomes across an outcome category in each patient, including the likelihoods of stable graft function, and T-cell-mediated and antibody-mediated rejection. This approach also identifies the presence or absence of an infection, including infection-related lymphoma. These capabilities have been developed and validated in multi-center studies to be reported at the World Transplant Congress in San Francisco, CA between August 2-6, 2025. "Plexision is redefining transplant diagnostics by predicting rejection subtypes and infection risks using blood tests derived from a single immune cell function platform," said Dr. Rakesh Sindhi, a transplant surgeon, Co-founder and Chief Scientific Officer, Plexision. The expanded use of AI will enhance the platform's ability to rank and predict the likelihood of multiple outcomes in each patient, making it a powerful clinical decision support tool for caregivers delivering precision transplant medicine. The company's proprietary technology delivers results in as little as 6 to 24 hours, enabling timely intervention. "This funding enables us to take the next step in making transplant care truly personalized. By expanding our artificial intelligence and machine learning capabilities, we are transforming how clinicians will interpret immunologic signals, moving from singular binary 'yes/no' answers to ranked predictions tailored to each patient," added Sindhi. All tests are performed at Plexision's CLIA-approved and CAP-accredited reference laboratory in Pittsburgh, PA, using blood samples shipped in from clinical partners. Results are used with other clinical data to optimize management of individual transplant patients. Plexision's innovations have demonstrated strong clinical performance. For example, the company's PlexABMR™ test recently predicted antibody-mediated rejection in kidney transplant recipients with 81% positive predictive value and 75% negative predictive value in a multi-center trial. Another test predicted EBV infection, a cause of life-threatening infection-related lymphoma in transplant patients. These findings will also be featured at the 2025 World Transplant Congress. To learn more about Plexision, visit or email info@ to schedule a meeting with the company at the World Transplant Congress. About Plexision Plexision's reference laboratory performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology. Transplant rejection testing services include the FDA-approved Pleximmune™ blood test to predict transplant rejection in children with liver or intestine transplants, the lab-developed Pleximark™ test to predict kidney transplant rejection, and the recently developed PlexABMR™ to predict antibody-mediated rejection. Tests that predict infection includes the lab-developed PlexCMV™, currently the most sensitive test to capture protective cell-mediated immunity in high-CMV-risk transplants. The PlexEBV™ test predicts EBV infection, which can cause post-transplant lymphoma. These tests measure cell-mediated immunity to cytomegalovirus and EBV, respectively. Plexision also performs custom R & D projects that require integration of cellular biomarker targets in all phases of development of drugs, vaccines, and gene therapy products, from pre-clinical to post-marketing. The company's portfolio of cell-based blood tests can be adapted to assess disease risk for several immunological disorders and develop personalized dosing recommendations. The company's reference laboratory in Pittsburgh, PA, is CLIA-approved, CAP-accredited and GMP-compliant. To learn more, visit or email info@ About Richard King Mellon Foundation Founded in 1947, the Richard King Mellon Foundation is the largest foundation in Southwestern Pennsylvania, and one of the 50 largest in the world. The Foundation's 2023 year-end net assets were $2.9 billion, and its Trustees in 2023 disbursed more than $176 million in grants and program-related investments. The Foundation focuses its funding on six primary program areas, delineated in its 2021-2030 Strategic Plan. View source version on Contacts Jason VancuraMarketbridge for Plexisionjvancura@
Yahoo
17 minutes ago
- Yahoo
Exagen Inc. (XGN): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thesis on Exagen Inc. on by inflection99. In this article, we will summarize the bulls' thesis on XGN. Exagen Inc.'s share was trading at $7.00 as of July 16th. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. Exagen (XGN) is a molecular diagnostics company specializing in autoimmune diseases like lupus and rheumatoid arthritis, primarily serving rheumatologists with its proprietary AVISE® test suite. Its flagship product, AVISE CTD, offers superior diagnostic capabilities versus the standard of care, combining multiple tests with enhanced sensitivity and specificity, reducing diagnosis time, hospitalizations, and repeat testing. The autoimmune diagnostics market is large, underserved, and economically attractive to all stakeholders—patients, providers, and payers—due to better outcomes, cost savings, and improved practice efficiency. This favorable market backdrop is amplified by the emergence of novel lupus therapies, increasing pharma's incentive to partner with diagnostics players like Exagen. The company holds key advantages through its proprietary biomarkers, unique reimbursement code, and growing coverage with Medicare and commercial payers. Recent innovations, such as new T-cell markers and early kidney disease detection, support pricing power, gross margin expansion, and potential biopharma revenue. Led by CEO John Aballi—who previously executed a similar playbook at Decipher before selling to Veracyte—Exagen has transformed from a cash-burning operation to near breakeven, with revenue acceleration, ASP tailwinds, and profitability expected by Q4 2025. Strategic interest is also plausible; Labcorp recently highlighted autoimmune disease as a priority area, positioning Exagen as a potential acquisition target. With minimal sell-side coverage, recent capital raises, and multiple upcoming catalysts—including improved reimbursement, guideline inclusion, and biopharma partnerships—Exagen is poised for a re-rating. Applying a conservative 4.5x 2026E revenue multiple implies 2.5–3x upside from current levels, while downside appears limited given the business's turnaround, strategic value, and current low-end peer valuation. Previously, we covered a bullish thesis on Oscar Health, Inc. (OSCR) by Oguz Erkan in May 2025, which highlighted the company's tech-driven platform, margin improvement, and expansion opportunity in ACA markets. The company's stock price has appreciated by approximately 21.62% since our coverage. This is because the thesis played out. Inflection99 shares a similar view on Exagen but emphasizes its autoimmune diagnostics advantage. Exagen Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held XGN at the end of the first quarter which was 7 in the previous quarter. While we acknowledge the potential of XGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
